Havens Advisors LLC Acquires New Stake in Cynapsus Therapeutics Inc. (CYNA)
Havens Advisors LLC purchased a new position in shares of Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSE:CTH) during the third quarter, according to its most recent filing with the SEC. The institutional investor purchased 47,500 shares of the company’s stock, valued at approximately $1,911,000. Cynapsus Therapeutics accounts for approximately 1.5% of Havens Advisors LLC’s portfolio, making the stock its 19th largest position. Havens Advisors LLC owned about 0.38% of Cynapsus Therapeutics at the end of the most recent quarter.
A number of research analysts recently commented on the stock. Janney Montgomery Scott downgraded shares of Cynapsus Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, September 1st. Noble Financial reaffirmed a “buy” rating and issued a $50.00 price target on shares of Cynapsus Therapeutics in a report on Tuesday, August 30th. Finally, BMO Capital Markets set a $30.00 price target on shares of Cynapsus Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 16th.
Cynapsus Therapeutics Company Profile
Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.
Receive News & Stock Ratings for Cynapsus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynapsus Therapeutics Inc. and related stocks with our FREE daily email newsletter.